Replies to post #470263 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Agreed.

[exwannabe]

Johnnygogo, I believe that NWBio is restricted from: (1) posting the DCVax-L trial results to its website, (2) talking about the trial results, (3) talking about regulatory approval pathways and BLA status, and (4) updating the endpoints on clinicaltrial.org because of agreements / embargoes with the journal article publisher.

I am fairly certain no reputable journal requires an embargo that violates the law.

I am fairly certain the presentation today would have violated any embargo.

[martyDg]

Then why they talked about the result today if they are still restricted? They literally showed us a slide version of TLD and yet they can’t still talk about it or pr? What kind of BS is that?

[Maverick0408]

If the clinicaltrial.org is updated with new endpoints, we jump back to over $2 and a lot more quickly. They have had 19 months to plan for this so it better come together this week!

[Troymister]

All probably true--but it still reflects a very poor communications strategy. Presentation at a science conference should have occurred after (shortly after or nearly simultaneous) to publication in a science journal and a PR release...not the other way around where the company is curtailed on what it can say or do.

The shorts had their way today and who knows how many tens of millions of shares big pharma purchased at less than $1 per share?

Congratulations to the scientists who have pursued what appears to be a remarkable advance in treatment of a terrible cancer. A Bronx cheer to management for the way it has handled communications. Again.